1. Emerging Concepts in Heart Failure

2. Goals

3. Overview

4. New Pharmacotherapies in Acute HF

5. Acute/Subacute HF Outcomes

6. RELAX-AHF

7. Serelaxin: RELAX-AHF-2

8. Biomarker Substudy

9. TRUE-AHF: Patient Disposition

10. Ularitide Exerted Expected Effects on Cardiac Distension and Intravascular Congestion

11. Effect of Ularitide on In-Hospital HF Events During First 120 Hours

12. Treatment of Preserved Cardiac Function HF With an Aldosterone anTagonist (TOPCAT)

13. Key Elements in a Trial Design

14. PRIMA II

15. Summary

16. Latest Data for New Therapies in Chronic HF

17. Ivabradine -- ACC/AHA/HFSA Guideline Update

18. Ivabradine: SHIFT Study

19. Pure Heart Rate Reduction Through If Current Inhibition

20. SHIFT: Ivabradine Efficacy Summary

21. Patient Selection: When to Consider Ivabradine

22. Ivabradine: Practical Considerations

23. Patiromer

24. Challenge of Balancing RAAS Inhibitor Use and Potassium Level

25. EMPA-REG Outcome: CV Death

26. Pharmacoeconomic Perspectives in HF

27. Hospitalizations and Healthcare Costs

28. Repeat HF Hospitalizations Predict Mortality

29. Mechanism of Action: Sacubitril/Valsartan

30. PARADIGM-HF: Sacubitril/Valsartan

31. Causes of Death in Patients With HF

32. Sacubitril/Valsartan Appears to Be Cost-Effective

33. CardioMEMS: CHAMPION Clinical Trial

34. Summary

35. Abbreviations

36. Abbreviations (cont)